Abstract
UCSF researchers have found that the majority of triple-negative breast cancers have a dysregulated MYC pathway and the group has shown that CDK inhibitors such as Merck and Ligand's dinaciclib could selectively kill off these tumors. The group is planning a clinical trial to test an undisclosed CDK inhibitor in this patient population.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
